However, benefits of Rac2 as therapeutic targets have not been previously explored, probably due to the lack of a Rac2-specific inhibitor as well as the fact that Rac2 deficiency results in primary immune deficiency and poor wound healing (Williams et al., 2000). The gene discussed is RAC2; the disease is Immunodeficiency.